Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Adaptive Biotechnologies Corp (DE:1HM)
FRANKFURT:1HM
RESEARCH TOOLSreports
Holding DE:1HM?
Track your performance easily
1HM Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€2.15 - €6.35
Previous Close€5.69
Volume0.00
Average Volume (3M)887.00
Market Cap
€848.95M
Enterprise Value€830.73M
Total Cash (Recent Filing)$243.33M
Total Debt (Recent Filing)$224.53M
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Feb 18, 2025EPS Estimate
-€0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding147,579,486
10 Day Avg. Volume512
30 Day Avg. Volume887
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)3.75
Price to Sales (P/S)4.99
Price to Cash Flow (P/CF)-8.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.69
Enterprise Value/Gross Profit8.77
Enterprise Value/Ebitda-5.08
Forecast
1Y Price Target
€7.31Price Target Upside28.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Adaptive Biotechnologies News
PremiumCompany Announcements
Adaptive Biotechnologies’ Q3 2024 Financial Performance Overview
1HM FAQ
What was Adaptive Biotechnologies Corp’s price range in the past 12 months?
Adaptive Biotechnologies Corp lowest stock price was €2.15 and its highest was €6.35 in the past 12 months.
What is Adaptive Biotechnologies Corp’s market cap?
Currently, no data Available
When is Adaptive Biotechnologies Corp’s upcoming earnings report date?
Adaptive Biotechnologies Corp’s upcoming earnings report date is Feb 18, 2025 which is in 58 days.
How were Adaptive Biotechnologies Corp’s earnings last quarter?
Adaptive Biotechnologies Corp released its earnings results on Nov 07, 2024. The company reported -€0.211 earnings per share for the quarter, beating the consensus estimate of -€0.276 by €0.065.
Is Adaptive Biotechnologies Corp overvalued?
According to Wall Street analysts Adaptive Biotechnologies Corp’s price is currently Undervalued.
Does Adaptive Biotechnologies Corp pay dividends?
Adaptive Biotechnologies Corp does not currently pay dividends.
What is Adaptive Biotechnologies Corp’s EPS estimate?
Adaptive Biotechnologies Corp’s EPS estimate is -€0.25.
How many shares outstanding does Adaptive Biotechnologies Corp have?
Adaptive Biotechnologies Corp has 147,579,480 shares outstanding.
What happened to Adaptive Biotechnologies Corp’s price movement after its last earnings report?
Adaptive Biotechnologies Corp reported an EPS of -€0.211 in its last earnings report, beating expectations of -€0.276. Following the earnings report the stock price went up 7.316%.
Which hedge fund is a major shareholder of Adaptive Biotechnologies Corp?
Among the largest hedge funds holding Adaptive Biotechnologies Corp’s share is Viking Global Investors LP. It holds Adaptive Biotechnologies Corp’s shares valued at 154M.
---
Adaptive Biotechnologies Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€7.31 (28.49% Upside)
€7.31 (28.49% Upside)
Blogger Sentiment
Bullish
DE:1HM Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.81%
12-Months-Change
Fundamentals
Return on Equity
-66.69%
Trailing 12-Months
Asset Growth
-22.18%
Trailing 12-Months
Company Description
Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.
---
1HM Company Deck
---
1HM Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong growth in MRD revenue and significant cost optimizations, with positive developments in both clinical and pharma sectors. However, challenges remain in Immune Medicine revenue and potential external impacts. Overall, the positive aspects significantly outweigh the negative trends.Read More>---
1HM Stock 12 Month Forecast
Average Price Target
€7.31
▲(28.49% Upside)
Technical Analysis
Adaptive Biotechnologies
―
Guardant Health
―
Twist Bioscience
―
QuidelOrtho
―
Exact Sciences
―
Best Analysts Covering 1HM
1 Year
1 Year Success Rate
5/13 ratings generated profit
1 Year Average Return
-0.05%
reiterated a buy rating last month
Copying David Westenberg's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of -0.05% per trade.
---